NCT06575933CompletedPhase 1
A Study of Calderasib (MK-1084) With Midazolam and Digoxin in Healthy Participants (MK-1084-009)
A Study to Evaluate the Effect of Single and Multiple Doses of MK-1084 on the Single-Dose Pharmacokinetics of Midazolam and Digoxin in Healthy Participants
Source: ClinicalTrials.gov · Last updated 11 Feb 2026
Brief summary (registry, in English)
The goal of the study is to see what happens to levels of midazolam and digoxin in a person's body over time (a pharmacokinetic or PK study). Researchers will compare what happens to midazolam and digoxin in the body when it is given with and without another medicine called calderasib. Researchers are testing if digoxin and midazolam levels in the body are different when digoxin and midazolam are given with or without calderasib.
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 28 (actual)
- First submitted
- 26 Aug 2024
- Start date
- 3 Sept 2024
- Primary completion date
- 28 Oct 2024
- Lead sponsor
- Merck Sharp & Dohme LLC
- Diseases
- Lung cancer
- NCT number
- NCT06575933
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 28
- From 3 Sept 2024 to the primary completion date, 28 Oct 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Has a history or presence of hypersensitivity or idiosyncratic reaction to the study drugs or related compounds
Other
- The key exclusion criteria include but are not limited to the following:
- Has a medical history that may confound the results of the study or poses an additional risk to the participant in the study
Who the study is looking for
- The key inclusion criteria include but are not limited to the following:
- Is medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vitals signs, and electrocardiograms (ECGs)
- Has a body mass index (BMI) ≥18 and ≤32 kg/m\^2, inclusive
Age in the registry: 18 years to 55 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Celerion ( Site 0001) Coordinator of this site? Confirm its status | Tempe | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.